Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05494645 · ClinicalTrials.gov registry record · Phase 4
Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery
A Phase 4 study, sponsored by St. Luke's Hospital, Pennsylvania.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT05494645: Completed Phase 4 study, sponsored by St. Luke's Hospital, Pennsylvania.
NCT05494645 is a Phase 4 study that has completed, run by St. Luke's Hospital, Pennsylvania. The registered enrollment target is 248 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05494645, a Phase 4 study, has completed, sponsored by St. Luke's Hospital, Pennsylvania.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
Liposomal Bupivacaine (Exparel) has been recently studied as the active agent utilized in various nerve block. Due to its liposomal form allowing for extended delivery, Exparel has been used in various peri-operative nerve blocks among multiple orthopaedic specialties in hopes of achieving improved pain control and decreased opioid use. This study compares the efficacy and effect on opioid use of peripheral nerve blocks and local infiltration with and without Exparel in patients undergoing foot and ankle surgery.
Interventions
- DRUG Exparel
- DRUG Peripheral Nerve Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2023-01-31 |
| Phase | Phase 4 |
What the finished NCT05494645 record still lists
NCT05494645 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Exparel is the first listed.
NCT05494645 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05494645 about?
NCT05494645 is a clinical study titled "Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery". Liposomal Bupivacaine (Exparel) has been recently studied as the active agent utilized in various nerve block. Due to its liposomal form allowing for extended delivery, Exparel has been used in various peri-operative nerve blocks among multiple orthopaedic specialties in hopes of achieving improved ...
What is the current status of trial NCT05494645?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2022-03-01. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT05494645?
The interventions under investigation include: Exparel (DRUG), Peripheral Nerve Block (DRUG).
Who is sponsoring clinical trial NCT05494645?
This trial is sponsored by St. Luke's Hospital, Pennsylvania, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05494645's enrollment target sits among peer trials
248 353rd of 2000 higher than 1,646 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI